Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A variety of diverse congenital and acquired conditions are associated with thrombocytopenia, and acquired thrombocytopenia is relatively common. Thrombocytopenia associated with the administration of chemotherapy or with surgical procedures are the most frequent indications for platelet transfusion. A prophylactic platelet transfusion threshold of 10 x 109/L is generally accepted for patients receiving cancer chemotherapy. Maintenance of a higher platelet count is indicated in a number of situations, including the settings of sepsis, DIC, hemorrhage, trauma, and surgery. Febrile and allergic reactions to platelet transfusion can often be managed conservatively with the administration of acetaminophen and diphenhydramine. Platelet refractoriness caused by nonimmune and immune mechanisms remains a major issue when repeated transfusions are required. HLA matching and platelet crossmatching are initial strategies to address immune platelet refractoriness. Antifibrinolytic agents may be useful adjuncts to platelet transfusion in the bleeding or platelet refractory patient. Because of the limitations of current storage techniques, research and development continue on platelet storage and substitutes. Thrombopoiesis-stimulating agents should provide additional therapeutic alternatives for the management of thrombocytopenia in specific settings. However, much additional research will be necessary in order to establish their safety and efficacy in patients receiving cancer chemotherapy.

Original publication





Book title

Rossi’s Principles of Transfusion Medicine

Publication Date



235 - 244